海昇药业：关于使用部分闲置募集资金购买理财产品的进展公告

Group 1 - The company, Haisheng Pharmaceutical, announced the use of idle raised funds amounting to 255 million yuan to purchase structured deposits from Hangzhou Bank, specifically the "Tianlibao" product [2] - The investment has a term of 25 days, with an expected annualized return ranging from 0.45% to 2.45% [2] - As of the announcement date, the balance of the financial products that have not yet matured is 255 million yuan, which represents 39.07% of the company's audited net assets for 2024 [2]